TABLE 6.

In vitro activities of antimicrobial agents against anaerobic organisms

Organism (no. of isolates)MIC50/MIC90 (μg/ml [% susceptible])a
ETPP/TA/CCMLVXMXF
Bacteroides fragilis groupb (51)0.5/4 (100)2/8 (100)0.5/8 (80)1/>32 (67)8/>16 (33)2/>16 (57)
Fusobacterium spp.c (10)≤.015/0.25 (100)≤0.06/2 (100)≤0.06/0.5 (100)≤0.06/2 (90)0.5/4 (80)0.25/2 (90)
Porphyromonas spp.d (53)≤0.015/≤0.015 (100)≤0.06/≤0.06 (100)≤0.06/0.125 (100)≤0.06/>32 (87)0.5/2 (91)0.5/1 (98)
Prevotella spp.e (66)0.125/0.25 (100)≤0.06/≤0.06 (100)≤0.25/2 (100)≤0.06/>32 (77)2/>16 (45)2/>16 (64)
Clostridium spp.f (20)0.03/1 (100)0.125/4 (100)≤0.06/0.5 (100)1/8 (80)0.25/16 (80)0.5/8 (80)
Finegoldia magna (110)0.06/0.125 (100)≤0.06/0.125 (100)0.125/0.25 (100)0.5/8 (81)8/>16 (40)2/16 (64)
Peptoniphilus asaccharolyticus (40)≤0.015/0.125 (100)≤0.06/0.125 (100)≤0.06/0.25 (100)0.25/>32 (78)4/>16 (35)0.5/16 (78)
Miscellaneous gram-positive coccig (77)0.06/0.25 (100)≤0.06/0.5 (100)≤0.06/0.25 (100)0.125/4 (90)4/>16 (62)1/16 (82)
Miscellaneous gram-positive rodsh (49)0.06/0.5 (100)≤0.06/4 (96)≤0.06/0.5 (100)≤0.06/>32 (84)0.5/8 (80)0.5/4 (88)
  • a ETP, ertapenem; P/T, piperacillin-tazobactam; A/C, amoxicillin-clavulanic acid; CM, clindamycin; LVX, levofloxacin; MXF, moxifloxacin.

  • b Bacteroides caccae (n = 2), B. distasonis (n = 1), B. fragilis (n = 19), B. ovatus (n = 7), B. stercoris (n = 4), B. thetaiotaomicron (n = 8), B. uniformis (n = 5), and B. vulgatus (n = 5).

  • c Fusobacterium nucleatum (n = 7) and Fusobacterium varium (n = 3).

  • d Porphyromonas asaccharolytica (n = 30), P. somerae (n = 21), P. catoniae (n = 1), and P. endodontalis (n = 1).

  • e Prevotella bivia (n = 29), P. corporis (n = 6), P. disiens (n = 5), P. enoeca (n = 1), P. intermedia (n = 3), P. melaninogenica (n = 11), P. oralis (n = 1) P. oris (n = 2), P. pallens (n = 1), P. tannerae (n = 2), P. veroralis (n = 1), and Prevotella spp. (n = 4).

  • f Clostridium aminovalericum (n = 1), C. cadaveris (n = 4), C. clostridioforme (n = 3), C. innocuum (n = 1), C. malenominatum (n = 1), C. perfringens (n = 6), C. septicum (n = 1), C. sphenoides (n = 1), and C. subterminale (n = 2).

  • g Peptostreptococcus anaerobius (n = 15), Peptostreptococcus micros (n = 7), Peptoniphilus harei (n = 4), Peptoniphilus indolicus (n = 1), Peptoniphilus ivorii (n = 1), Peptoniphilus lacrimalis (n = 1), Anaerococcus prevotii (n = 14), Anaerococcus octavius (n = 1), Anaerococcus tetradius (n = 9), Anaerococcus vaginalis (n = 7), Gemella morbillorum (n = 3), Ruminococcus productus (n = 1), and anaerobic gram-positive cocci (n = 13).

  • h Eubacterium lentum (n = 1), Eubacterium limosum (n = 1), Eubacterium nodatum (n = 1), Eubacterium saburreum (n = 1), Eubacterium spp. (n = 13), Propionibacterium acnes (n = 19) Propionibacterium sp. (n = 1), Actinomyces meyeri (n = 1), Actinomyces odontolyticus (n = 1), Actinomyces turicensis (n = 1), Arcanobacterium pyogenes (n = 1), Corynebacterium CDC group G-like (anaerobic) (n = 2), Lactobacillus brevis (n = 1), Lactobacillus casei (n = 1), Lactobacillus plantarum (n = 2), Lactobacillus uli (n = 1), and an unusual gram-positive bacillus (n = 1).